Lauren Veltri1, Aaron Cumpston2, Alexandra Shillingburg2, Sijin Wen3, Jin Luo3, Sonia Leadmon4, Kathy Watkins4, Michael Craig4, Mehdi Hamadani5, Abraham S Kanate6. 1. Section of Hematology/Oncology, Department of Internal Medicine, West Virginia University, Morgantown, West Virginia, USA. 2. Department of Pharmacy, West Virginia University, Morgantown, and West Virginia Osborn Hematopoietic Malignancy and Transplantation Program, West Virginia University, Morgantown, West Virginia, USA. 3. Department of Biostatistics, West Virginia University, Morgantown, West Virginia, USA. 4. Osborn Hematopoietic Malignancy and Transplantation Program, West Virginia University, Morgantown, West Virginia, USA. 5. Division of Hematology-Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 6. Osborn Hematopoietic Malignancy and Transplantation Program, West Virginia University, Morgantown, West Virginia, USA. Electronic address: askanate@hsc.wvu.edu.
Abstract
BACKGROUND AIMS: Hematopoietic cell mobilization with granulocyte-colony stimulating factor (G-CSF) and plerixafor results in superior CD34+ cell yield compared with G-CSF alone in patients with myeloma and lymphoma. However, plerixafor-based approaches may be associated with high costs. Several institutions use a "just-in-time" plerixafor approach, in which plerixafor is only administered to patients likely to fail mobilization with G-CSF alone. Whether such an approach is cost-effective is unknown. METHODS: We evaluated 136 patients with myeloma or lymphoma who underwent mobilization with 2 approaches of plerixafor utilization. Between January 2010 and October 2012, 76 patients uniformly received mobilization with G-CSF and plerixafor. Between November 2012 and June 2014, 60 patients were mobilized with plerixafor administered only to those patients likely to fail mobilization with G-CSF alone. RESULTS: The routine plerixafor group had a higher median peak peripheral blood CD34+ cell count (62 versus 29 cells/μL, P < 0.001) and a higher median day 1 CD34+ yield (2.9 × 10(6) CD34+ cells/kg versus 2.1 × 10(6) CD34+ cells/kg, P = 0.001). The median total CD34+ collection was higher with routine plerixafor use (5.8 × 10(6) CD34+ cells/kg versus 4.5 × 10(6) CD34+ cells/kg, P = 0.007). In the "just-in-time" group, 40% (n = 24) completed adequate collection without plerixafor. There was no difference in mobilization failure rates. The mean plerixafor doses used was lower with "just-in-time" approach (1.3 versus 2.1, P = 0.0002). The mean estimated cost in the routine plerixafor group was higher (USD 27,513 versus USD 23,597, P = 0.01). DISCUSSION: Our analysis demonstrates that mobilization with a just-in-time plerixafor approach is a safe, effective, and cost-efficient strategy for HPC collection.
BACKGROUND AIMS: Hematopoietic cell mobilization with granulocyte-colony stimulating factor (G-CSF) and plerixafor results in superior CD34+ cell yield compared with G-CSF alone in patients with myeloma and lymphoma. However, plerixafor-based approaches may be associated with high costs. Several institutions use a "just-in-time" plerixafor approach, in which plerixafor is only administered to patients likely to fail mobilization with G-CSF alone. Whether such an approach is cost-effective is unknown. METHODS: We evaluated 136 patients with myeloma or lymphoma who underwent mobilization with 2 approaches of plerixafor utilization. Between January 2010 and October 2012, 76 patients uniformly received mobilization with G-CSF and plerixafor. Between November 2012 and June 2014, 60 patients were mobilized with plerixafor administered only to those patients likely to fail mobilization with G-CSF alone. RESULTS: The routine plerixafor group had a higher median peak peripheral blood CD34+ cell count (62 versus 29 cells/μL, P < 0.001) and a higher median day 1 CD34+ yield (2.9 × 10(6) CD34+ cells/kg versus 2.1 × 10(6) CD34+ cells/kg, P = 0.001). The median total CD34+ collection was higher with routine plerixafor use (5.8 × 10(6) CD34+ cells/kg versus 4.5 × 10(6) CD34+ cells/kg, P = 0.007). In the "just-in-time" group, 40% (n = 24) completed adequate collection without plerixafor. There was no difference in mobilization failure rates. The mean plerixafor doses used was lower with "just-in-time" approach (1.3 versus 2.1, P = 0.0002). The mean estimated cost in the routine plerixafor group was higher (USD 27,513 versus USD 23,597, P = 0.01). DISCUSSION: Our analysis demonstrates that mobilization with a just-in-time plerixafor approach is a safe, effective, and cost-efficient strategy for HPC collection.
Authors: S Sinha; M A Gertz; M Q Lacy; A Dispenzieri; S R Hayman; F K Buadi; D Dingli; I N Micallef; W J Hogan; D A Gastineau; S V Rajkumar; S K Kumar Journal: Leukemia Date: 2011-10-28 Impact factor: 11.528
Authors: Peter Gambell; Kirsten Herbert; Michael Dickinson; Kerrie Stokes; Mathias Bressel; Dominic Wall; Simon Harrison; H Miles Prince Journal: Biol Blood Marrow Transplant Date: 2012-01-03 Impact factor: 5.742
Authors: T Philip; C Guglielmi; A Hagenbeek; R Somers; H Van der Lelie; D Bron; P Sonneveld; C Gisselbrecht; J Y Cahn; J L Harousseau Journal: N Engl J Med Date: 1995-12-07 Impact factor: 91.245
Authors: John F DiPersio; Ivana N Micallef; Patrick J Stiff; Brian J Bolwell; Richard T Maziarz; Eric Jacobsen; Auayporn Nademanee; John McCarty; Gary Bridger; Gary Calandra Journal: J Clin Oncol Date: 2009-08-31 Impact factor: 44.544
Authors: Farrukh T Awan; S Thomas Kochuparambil; David Deremer; Aaron Cumpston; Michael Craig; Anand Jillella; Mehdi Hamadani Journal: J Oncol Date: 2012-04-10 Impact factor: 4.375
Authors: Carlos H Villa; Thomas Porturas; Mary Sell; Mark Wall; Gene DeLeo; Jenna Fetters; Sam Mignono; Leah Irwin; Wei-Ting Hwang; Una O'Doherty Journal: Transfusion Date: 2017-12-11 Impact factor: 3.157
Authors: Andrew Johnsrud; Abdullah Ladha; Lori Muffly; Parveen Shiraz; Gary Goldstein; Victoria Osgood; Judith A Shizuru; Laura Johnston; Sally Arai; Wen-Kai Weng; Robert Lowsky; Andrew R Rezvani; Everett H Meyer; Matthew J Frank; Robert S Negrin; David B Miklos; Surbhi Sidana Journal: Transplant Cell Ther Date: 2021-04-26
Authors: B M Haverkos; Y Huang; P Elder; L O'Donnell; D Scholl; B Whittaker; S Vasu; S Penza; L A Andritsos; S M Devine; S M Jaglowski Journal: Bone Marrow Transplant Date: 2017-01-09 Impact factor: 5.483
Authors: Anna Sureda; Christian Chabannon; Tamás Masszi; David Pohlreich; Christof Scheid; Catherine Thieblemont; Björn E Wahlin; Ioanna Sakellari; Nigel Russell; Andrea Janikova; Anna Dabrowska-Iwanicka; Cyrille Touzeau; Albert Esquirol; Esa Jantunen; Steffie van der Werf; Paul Bosman; Ariane Boumendil; Qianying Liu; Marina Celanovic; Silvia Montoto; Peter Dreger Journal: Bone Marrow Transplant Date: 2019-09-30 Impact factor: 5.483